Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review

BACKGROUND AND OBJECTIVE: Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3–7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) for the treatment of patients with ALK-positive l...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Aakash, Lovly, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087990/
https://www.ncbi.nlm.nih.gov/pubmed/37057106
http://dx.doi.org/10.21037/tlcr-22-708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087990/
https://www.ncbi.nlm.nih.gov/pubmed/37057106
http://dx.doi.org/10.21037/tlcr-22-708

Ejemplares similares